A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

DSCN-GRV AECOPD-CSIS-001

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation. Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections. This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.

2022-08-10

2024-09-30

2024-12-31

Recruiting

Early phase I

268

Inclusion Criteria: * Age ≥ 40; * History of moderate to very severe COPD with a post-bronchodilator Forced Expiratory Volume in One Second/Forced Vital Capacity (FEV1/FVC) \< 70% and a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) \< 80% of predicted normal value within one year prior to enrollment; * History of one or more acute exacerbations within one year prior to enrollment; * At least 6 weeks of stable disease prior to enrollment; * The acute exacerbation is classified as Anthonisen I (with 3 main symptoms of worsening dyspnea, increased sputum volume and sputum purulence) or II (with sputum purulence and another main symptom); * Participants can be treated on an outpatient basis after clinical assessment. Exclusion Criteria: * Anthonisen III acute exacerbation (Have two major symptoms of worsening dyspnea and increased sputum volume or one of the two major symptoms) * Hospitalization or intensive care unit (ICU) treatment is required * Sputum culture within the previous year indicated the presence of pathogenic microorganisms resistant to quinolones * Quinolone allergy * History of QTc prolongation, or need for medications to treat QTc prolongation (e.g., Class Ia or Class III antiarrhythmics); * Definite pulmonary disease other than COPD (asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, pulmonary fibrosis, lung cancer) * History of severe cardiovascular disease (e.g., congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke within 6 months, clinically significant arrhythmia, previous history of aortic aneurysm or aortic dissection, positive family history, or risk factors (e.g., Marfan syndrome), poorly controlled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg on 2 or more consecutive measurements) * Severe systemic diseases, such as severe dizziness, headache and other nervous system diseases * Malignant tumor * Concomitant or history of tendon disease or myasthenia gravis or Parkinson's disease * Abnormal liver function, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level \> 3 times the upper limit of normal, and/or total bilirubin level \>2 times the upper limit of normal * With moderate or severe decline of renal function, endogenous creatinine clearance rate (Ccr) \< 50ml/min * History of seizure, or psychiatric condition that could affect compliance with the protocol, or risk for suicide, or history of alcohol or illicit drug abuse * Immunocompromised participants using glucocorticoids (total dose equivalent to prednisone 20 mg daily for more than 2 weeks) or immunosuppressive agents or HIV infected participants * Gastrointestinal disorders that may affect drug absorption (e.g., active Crohn's disease, active ulcerative colitis) * Pregnant or lactating women or women of childbearing potential who are planning to become pregnant * Participation in other clinical trials within 3 months prior to screening * Used antibiotics (including systemic and inhalation) 30 days before enrollment * Serum potassium \< 3.5mmol/L at screening, or repeated hypokalemia that was difficult to correct in the past * Other reasons that the investigator considered inappropriate to participate in the study.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 268, 'type': 'ESTIMATED'}}

2024-04-10